Full Press Release Details
signs lease to move into larger building.
a provider of pain management systems and electrotherapy products for medical
patients with functional disability, announces it has signed a lease to rent a
75,000 square foot building in Lone Tree (Littleton), Colorado. Zynex currently
leases 16,553 square feet in Littleton, Colorado and the new building will house
its headquarters, office, plant and warehouse.
Sandgaard, CEO of Zynex comments: "This is an exciting time for Zynex. The move
to our new headquarters comes at a time where we have recently paid down our
Line of Credit entirely and placed advertising to add 25 more sales
representatives in major cities across the country. We had already outgrown the
current space and will have room to grow in the new building for several
Inc. (founded in 1996) engineers, manufactures, markets and sells its own design
of electrotherapy medical devices in two distinct markets: standard digital
electrotherapy products for pain relief and pain management; and the
for stroke and spinal cord injury (SCI) rehabilitation. Zynex's product lines
are fully developed, FDA-cleared, commercially sold, an have been developed to
uphold the Company's mission of improving the quality of life for patients
suffering from impaired mobility due to stroke, spinal cord injury, or
debilitating and chronic pain.
statements in this release are "forward-looking" and as such are subject to
numerous risks and uncertainties. Actual results may vary significantly from the
results expressed or implied in such statements. Factors that could cause actual
results to materially differ from forward-looking statements include, but are
not limited to, the need to obtain additional capital in order to grow our
business, larger competitors with greater financial resources, the need to keep
pace with technological changes, our dependence on the reimbursement from
insurance companies for products sold or rented to our customers, acceptance of
our products by health insurance providers, acceptance of our products by
hospitals and clinicians, our dependence on third party manufacturers to produce
our goods on time and to our specifications, implementation of our sales
strategy including a strong direct sales force, the uncertain outcome of pending
material litigation and other risks described in our 10-K Report for the year
ended December 31, 2008.
Thomas Sandgaard, CEO. (303) 703-4906, www.zynexmed.com